The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focussed on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.
EBiSC, the European Bank for induced pluripotent Stem Cells announces the public launch of its on-line catalogue of induced Pluripotent Stem Cells (iPSCs) which are available to academic and commercial scientists for use in disease modelling and other forms of pre-clinical research. (https://cells.ebisc.org).
Edinburgh, Scotland, 28th January 2016 Roslin Cell Sciences, a wholly owned subsidiary of Roslin Cells Ltd, has moved its operations for production of human pluripotent stem cells (iPSCs) for drug discovery to the Roslin BioCentre.
Roslin Cells announces the creation of two commercially focused subsidiaries: Roslin Cell Therapies and Roslin Cell Sciences
Edinburgh, Scotland, 11th January 2016 Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations.
Cell Therapy Catapult & Roslin Cells to create clinical grade stem cells to accelerate research into new treatments
London and Edinburgh, UK - 11 September 2013: The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation's health and wealth, and Roslin Cells, an expert in the production of stem cells, are partnering to establish a source of clinical grade induced pluripotent stem cells.....
Roslin Cells is Granted an MIA(IMP) and Manufacturer's 'Specials' Licence for Cellular Therapy Facility
Edinburgh, Scotland Roslin Cells Ltd, announced today that its GMP Cellular Therapy Manufacturing Facility within the Scottish Centre for Regenerative Medicine has recently been licensed by the Medicines Healthcare Products Regulatory Agency (MHRA) for the manufacture of human cell therapy products.
Edinburgh, Scotland - 16 April 2013. Roslin Cells Ltd, world leaders in the development of cell therapies and pluripotent stem cells for applications in research, drug discovery and therapy, has achieved the prestigious Investors in People Accreditation. This is the most successful framework for...
Edinburgh, Scotland – 05 March 2012: Roslin Cells Ltd, announced today that it will be participating in a consortium to generate human induced pluripotent stem cells (iPS cells) to study bipolar affective disorder...
Edinburgh, Scotland – 23 November 2011: Roslin Cells Ltd., world leaders in the isolation of new clinical grade pluripotent stem cells, announced today that it has now moved to the new Scottish Centre for Regenerative Medicine at Edinburgh BioQuarter.
Pluripotent Stem Cell Evaluation Agreement between Roslin Cells and Pfizer for regenerative medicine development.
UK, July 2011 – Roslin Cells and Pfizer Limited have signed an agreement for Pfizer to evaluate Roslin’s GMP quality Pluripotent Stem Cells (PSC).